Campaign helps kids recognize OCD
Solvay Pharmaceuticals, Pharmacia & Upjohn Inc. and the Obsessive Compulsive Foundation have launched a new public awareness campaign to help children and adults recognize and treat obsessive-compulsive disorder.
Solvay Pharmaceuticals, Pharmacia & Upjohn Inc. and the Obsessive Compulsive Foundation have launched a new public awareness campaign to help children and adults recognize and treat obsessive-compulsive disorder.
The campaign, "Kids Like Me," will include a children's book, a brochure for parents, a toll-free OCD information line, a Website and television public service announcements featuring former game show host Marc Summers, who has OCD.
OCD is a biological brain disorder thought to be caused by an imbalance of the brain chemical seratonin.
According to a recent national survey, adults who had OCD while growing up waited an average of nearly 20 years before they sought treatment. Embarrassment, lack of knowledge about the disorder and fear of becoming misunderstood were the most commonly cited reasons for keeping silent.
The survey was conducted by Ketchum Public Relations Research and Measurement Department. It was sponsored by Solvay, based in Marietta, GA, and Pharmacia & Upjohn of Kalamazoo, MI. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
